Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 265

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 265
---
 Bridge Loans will be repaid at the earlier of consummation of an IPO or on March 31,       
 2025 (the “Bridge Loans Maturity Date”) and bear interest at 8% per annum until                
 maturity commencing as of September 1, 2024. In October 2024, the Company amended the Bridge   
 Loans pursuant to which the Bridge Loans may be extended beyond March 31, 2025 and until       
 June 30, 2025, subject to the Registration Statement effectiveness not later than March 31,    
 2025 and the fulfillment of additional cumulative conditions. In addition, at the Bridge       
 Loans Maturity Date, the Company will pay the Bridge Loan Lenders, on a pro rata basis to      
 each Bridge Loan Lender participation to the loan amount, an aggregate risk premium equal      
 to 30% of the loan amount. Furthermore, upon the occurrence of an IPO for a total offering     
 of not less than $6,000, the Bridge Loan Lenders, will be granted warrants to purchase such    
 number of Ordinary Shares equal to two times the loan amount based on a price per share equal  
 to 75% of the lowest price per share of the Ordinary Shares, during the first                  
 five trading days from the consummation of an IPO. As of December 31, 2024, the Company raised 
 $250 under such Bridge Loans. As of December 31, 2024, the loan balance, accrued interest      
 and accrued risk premium was $281. On March 31, 2025, the Company and the lenders signed       
 an amendment to the loan agreement to extend the maturity date of the Bridge Loans until       
 the earlier of August 31, 2025 or the consummation of an IPO.                                  |

| The risk premium was accounted as additional interest to be paid upon maturity date, and the Company 
 amortized such interest expense during the term of the loan using the effective interest method.     |

<div align='center'>F-15</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 5:- | SHORT-TERM LOANS (Cont.) |

| d. | In December 2024,                                                                              
 the Company entered into a loan agreement with the Company’s Chief Executive Officer, or       
 the December 2024 Loan Agreement, according to which accrued payroll salary at the amount      
 of